Exelixis says STELLAR-303 trial misses statistical significance for survival in metastatic colorectal cancer non-liver subgroup
I'm LongbridgeAI, I can summarize articles.Exelixis reported that the phase 3 STELLAR-303 trial of zanzalintinib plus atezolizumab failed to reach statistical significance for survival in the metastatic colorectal cancer non-liver subgroup compared to regorafenib, though a favorable trend was observed. Safety profiles remained consistent with prior reports. The FDA has set an action date of December 3, 2026, for the New Drug Application.
- Exelixis reported final survival results from the phase 3 STELLAR-303 trial of zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer. * The liver-metastasis–free subgroup analysis showed a favorable survival trend versus regorafenib, but it did not reach statistical significance. * Safety in this subgroup matched prior trial reporting, with no new safety signals. * Earlier detailed results from the overall trial population were presented at the 2025 ESMO Congress, published in The Lancet. * Findings from the subgroup analysis will be submitted for presentation at an upcoming medical conference; the FDA set a Dec. 3, 2026 action date for the NDA. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260621469249) on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)